Allogene Therapeutics Inc. experiences surge after Baird remains bullish on CAR-T therapy

From Stocktwits: 2025-02-24 00:22:12

Allogene Therapeutics Inc. saw a 42% surge last week after Baird remained bullish on the company, citing the updated cema-cel data supporting the durability of its allogeneic CAR-T therapy. Short interest in the stock hit a multi-year low of 20% in mid-January but has since risen to 23.6%, indicating lingering bearish sentiment. Retail sentiment on Stocktwits has turned ‘extremely bullish’ with message volume up 1,200%. Allogene also received FDA clearance to begin Phase 1 trials for its ALLO-329 drug candidate in systemic lupus erythematosus. Shares are down nearly 1.4% year-to-date, despite positive news and analyst outlooks.



Read more at Stocktwits: Analyst Sees CAR-T Therapy Promise